Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects

Imke Hagen; Dominik M Schulte; Nike Müller; Jessica Martinsen; Kathrin Türk; Jürgen Hedderich; Stefan Schreiber; Matthias Laudes

doi:10.1016/j.cyto.2015.02.022

Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects

Cytokine. 2015 Jun;73(2):265-9. doi: 10.1016/j.cyto.2015.02.022. Epub 2015 Mar 21.

Authors

Imke Hagen¹, Dominik M Schulte², Nike Müller³, Jessica Martinsen³, Kathrin Türk³, Jürgen Hedderich⁴, Stefan Schreiber³, Matthias Laudes⁵

Affiliations

¹ Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany. Electronic address: [email protected].
² Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany. Electronic address: [email protected].
³ Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany.
⁴ Institute of Medical Informatics and Statistics, University of Kiel, Brunswiker Straße 10, 24105 Kiel, Germany.
⁵ Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany. Electronic address: [email protected].

PMID: 25802195
DOI: 10.1016/j.cyto.2015.02.022

Abstract

Introduction: Obesity is associated with low-grade systemic inflammation which is thought to trigger the development of comorbidities such as type 2 diabetes. The soluble receptor for advanced glycation end products (sRAGE) belongs to the innate immune system and has been linked to obesity, recently. The aim of the present study was to examine whether serum sRAGE concentrations are related to the grade of weight loss and improvement of insulin resistance due to a very low calorie diet (VLCD).

Methods: 22 severe obese subjects (Median Body Mass Index (BMI): 44.5kg/m(2)) were included in a dietary intervention study of 6month, consisting of a very low calorie formula diet phase (VLCD: 800kcal/d) for 12 weeks and a following 12 week weight maintenance phase. Fasting glucose, fasting insulin, adiponectin, leptin and sRAGE were determined from sera. Insulin sensitivity was estimated by Homeostasis Model Assessment (HOMA) index and leptin-to-adiponectin-ratio (LAR).

Results: Mean body weight reduction by VLCD accounted to 21.7kg with a significant improvement of insulin resistance. At baseline, sRAGE serum levels were significantly inversely related to BMI (rS=-0.642, p=0.001) and HOMA (rS=-0.419, p=0.041). Of interest, sRAGE serum levels at baseline were significantly lower in study subjects with greater reduction of BMI (p=0.017). In addition, a significantly greater HOMA reduction was observed in subjects with lower sRAGE serum levels at baseline (p=0.006). Finally, correlation analysis revealed, that changes of sRAGE serum levels were significantly correlated to changes of BMI (rS=-0.650, p=0.022) during intervention.

Conclusion: Anti-inflammatory sRAGE might be a potential future biomarker to predict weight loss and improvement of insulin resistance by a VLCD whereby lower baseline sRAGE serum levels indicate a better outcome of the dietary intervention.

Keywords: Biomarker; Dietary intervention; Soluble receptor for advanced glycation end products; Very low calorie diet.

Publication types

Clinical Trial

MeSH terms

Anthropometry
Biomarkers / blood
Body Mass Index
Caloric Restriction*
Female
Humans
Insulin / metabolism*
Insulin Resistance
Male
Middle Aged
Obesity / blood*
Obesity / diet therapy*
Receptor for Advanced Glycation End Products / blood*
Solubility
Weight Loss*

Substances

Biomarkers
Insulin
Receptor for Advanced Glycation End Products